Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data
Rattachement africain : il, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) has emerged as a potential strategy to improve resectability and reduce morbidity in advanced DTC. We evaluated the efficacy and safety of neoadjuvant TKI therapy in patients with advanced or unresectable DTC. METHODS: A retrospective study was conducted on patients with advanced DTC treated with neoadjuvant TKIs (lenvatinib or dabrafenib/trametinib) followed by curative intent surgery between 2023 and 2025. Data on disease extent, genetic alterations, treatment regimens, and adverse effects were collected. Radiologic response was assessed by CT or PET-CT according to the RECIST 1.1 criteria. Surgical outcomes were evaluated by the degree of morbidity and by tumour involvement in the surgical margins. RESULTS: Nine patients were included, seven treated with lenvatinib, two treated with dabrafenib/trametinib on the basis of molecular alterations. The median duration of TKI therapy was 5 months, and no disease progression was observed throughout. Radiological assessment revealed a median reduction in tumour burden of 23.53%, contributing to improved tumour resectability. All patients underwent surgical resection with preservation of critical structures. Elevated TSH levels during neoadjuvant therapy was correlated with a positive treatment response (p = 0.028). CONCLUSIONS: Neoadjuvant TKIs may improve the surgical outcomes of patients with advanced DTC. Decision-guided radiological and blood-based surrogate biomarkers, such as TSH, can assist in evaluating treatment response and guide decisions regarding treatment duration and extent of surgical resection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data
- Date Crossref
- 05/11/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tel Aviv University pays non établi dans la noticeUniversité ou école supérieure
-
Tel Aviv Sourasky Medical Center Oncology Division pays non établi dans la noticeÉtablissement de santé
-
Ben-Gurion University of the Negev pays non établi dans la noticeUniversité ou école supérieure
-
Barzilai Medical Center pays non établi dans la noticeÉtablissement de santé
-
Sheba Medical Center pays non établi dans la noticeÉtablissement de santé
-
Assuta Medical Center pays non établi dans la noticeÉtablissement de santé
-
Temple University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Otolaryngology Head & pays non établi dans la noticeOrganisation à but non lucratif
-
The Faculty of Medical and Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Institute of Radiology pays non établi dans la noticeStructure de recherche
-
Department of Otorhinolaryngology pays non établi dans la noticeOrganisation à but non lucratif
-
Faculty of Health Sciences Ben Gurion University of Negev Beer Sheba Israel pays non établi dans la noticeUniversité ou école supérieure
Tel Aviv University, Oncology Division — Tel Aviv Sourasky Medical Center et Ben-Gurion University of the Negev, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.